

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09402820
	Filing Date		1999-10-12
	First Named Inventor	Benjamin Chain	
	Art Unit		1645
	Examiner Name	P. A. Duffy	
Attorney Docket Number		20555/1203301-US1	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5441870		1995-08-15	Seubert et al.	
	2	5688651		1997-11-18	Solomon et al.	
	3	5721130		1998-02-24	Seubert et al.	
	4	4741901		1988-05-03	Levinson et al.	
	5	5593846		1997-01-14	Schenk et al.	
	6	5604102		1997-02-18	McConlogue et al.	
	7	6287793	B1		Schenk, et al.	
	8	6610493	B1	2003-08-26	Citron et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402820
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

9	6710226		2004-03-23	Schenk	
10	6717031	A1	2004-04-06	Games et al.	
11	6743427			Schenk	
12	6761888		2004-07-13	Schenk	
13	6905686		2005-06-14	Schenk	
14	6913745		2005-07-05	Schenk	
15	6923964		2005-08-02	Schenk	
16	5231000		1993-07-27	Majocha et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402820
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
1	1	89/01975	WO		1989-03-09	Celltech Ltd		<input type="checkbox"/>
2	2	96/18900	WO		1996-06-20	Univ Ramot et al.		<input type="checkbox"/>
3	3	0683234	EP		1995-11-22	Takeda Chemical Industries Ltd		<input type="checkbox"/>
4	4	96/25435	WO		1996-08-22	Bayer Ag		<input type="checkbox"/>
5	5	99/27944	WO		1999-06-10	Athena Neurosciences Inc et al.		<input type="checkbox"/>
6	6	98/44955	WO		1998-10-15	Mindset Ltd et al.		<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button								Add
NON-PATENT LITERATURE DOCUMENTS								Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵
	1	Solomon et al, Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide Proc. Natl. Acad. Sci. USA, January 1996, Vol. 93, pages 452-455						<input type="checkbox"/>
	2	Solomon et al, Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA, April 1997, Vol. 94, pages 4109-4112.						<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402620
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

3	Hanan et al. Inhibitory effect of monoclonal antibodies on Alzheimer's beta-amyloid peptide aggregation. Amyloid. Int. H. Exp. Clin. Invest. 1996, Vol. 3, pages 130-133.	<input type="checkbox"/>
4	Jones et al. Antibodies for Targeted Gene Therapy: Extracellular Gene Targeting and Intracellular Expression. Advanced Drug Delivery Reviews. 1988, Vol. 31, pp. 153-170.	<input type="checkbox"/>
5	Marasco et al. Design, Intracellular Expression, and Activity of a Human Anti- Human Immunodeficiency Virus Type 1 gp 120 Single-Chain Antibody. Proc. Natl. Acad. Sci. (USA). August 1993, vol. 90, pp. 7889-7893.	<input type="checkbox"/>
6	Seubert et al. Secretion of B-Amyloid Precursor Protein Cleaved at the Amino Terminus of the B-Amyloid Peptide Nature. 21 January 1993, Vol. 361 pp. 260-263.	<input type="checkbox"/>
7	Nakamura et al. Carboxyl End- Specific Monoclonal Antibodies to Amyloid B Protein (AB) subtypes (AB40 and AB42 (43) Differentiate AB in Senile Plaques and Amyloid Angiopathy in Brains of Aged Cynomolgus Monkeys. Neurosci. Lett. 1995, Vol. 201, pp. 151-154.	<input type="checkbox"/>
8	Bourbonniere et al. Expression of Amyloid Precursor Protein in a Neuronal Cell Line: Functional Activity of Proximal Regulatory Elements. Molecular Brain Research. 1993, Vol. 19, pp. 246-250.	<input type="checkbox"/>
9	Le Gai La Salle et al. Ad Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain. Science. 12 February 1993, Vol. 259, pp. 988-990.	<input type="checkbox"/>
10	Yang et al. Optimizing Liposome-Mediated Gene Transfer in Primary Rat Septo-Hippocampal Cell Cultures. Neurosci. Lett. 1994, vol. 182, pp. 287-290.	<input type="checkbox"/>
11	Cheng, P-W. Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin. Human Gene Therapy. February 10, 1996, Vol. 7, pp. 275-282.	<input type="checkbox"/>
12	Steinberg, D. News. Companies Halt First Alzheimer Vaccine Trial. The Scientist. 01 April 2002, Vol. 16, pp. 1-6.	<input type="checkbox"/>
13	Gravina et al. "Amyloid b Protein (Ab) in Alzheimer's Disease Brain: Biochemical and Immunocytochemical Analysis with Antibodies Specific for Forms Ending at Ab 40 or Ab42(43)", J Biol Chem 270(13):7013-7016 (1995).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402620
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

14	Harrington et al, "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptid corresponding to the C-terminus of b/A4-protein", Biochim Biophys Acta 1158, 120-127	<input type="checkbox"/>
15	Gravina SA et al, "Amyloid beta protein (A beta) in Alzheimer's Disease brain: Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43)," J Biol Chem 270 (13):7013-7016 (1995).	<input type="checkbox"/>
16	Harrington CR et al, "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of beta/A4-protein," Biochim Biophys Acta 1158 (2):120-128 (1993).	<input type="checkbox"/>
17	Higgins et al, "Transgenic Mouse Brain Histopathology Resembles Early Alzheimer's Disease," Ann Neurol 35:598-607 (1994).	<input type="checkbox"/>
18	Iwatsubo T et al, "Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)," Neuron 13(1):45-53 (1994).	<input type="checkbox"/>
19	Iwatsubo et al, "Amyloid b Protein (AB) Deposition: AB 42(43) Precedes AB40 in Down Syndrome", Ann Neurol 37:294-299 (1995).	<input type="checkbox"/>
20	Konig, G et al., "Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide," Ann NY Acad Sci 777:344-355 (1996).	<input type="checkbox"/>
21	Murphy, GM Jr. et al. "Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's Disease and related disorders Am J Path 144(5): 1082-1088 (1994).	<input type="checkbox"/>
22	Mann et al, "The Extent of Amyloid Deposition in Brain in patients with Down's Syndrome does not depend upon the Apolipoprotein E genotype", Neurosci Letter 196(1-2): 105-108 (1995)	<input type="checkbox"/>
23	MANN et al, Predominant Deposition of Amyloid-B42(43) in Plaques in Cases of Alzheimer's Disease and Hereditary Cerebral Hemorrhage Associated with Mutations in the Amyloid Precursor Protein Gene", Am J Pathol 148(4): 1257-1265 (1996)	<input type="checkbox"/>
24	Mann et al, "Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta 42(43)", Ann Neurol 40(2): 149-156 (1996).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402820
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

25	Nakamura et al, "Carboxyl end-specific monoclonal antibodies to amyloid beta protein (A beta) subtypes (A beta 40 and A beta 42(43)) differentiate A beta in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys", <i>Neurosci Letter</i> 201 (2): 151-154 (1996).	<input type="checkbox"/>
26	Saïdo et al, "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain", <i>J Biol Chem</i> 268(33): 25239-25243 (1993).	<input type="checkbox"/>
27	Suzuki et al, "High Tissue content of Soluble b1-40 is Linked to Cerebral Amyloid Angiopathy", <i>Am J Pathol</i> 145(2): 452-460 (1994).	<input type="checkbox"/>
28	Tamaoka et al, "Amyloid b protein 1-42/43 (Ab 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study", <i>Brain Res.</i> 679: 151-156 (1995).	<input type="checkbox"/>
29	Tsuzuki et al, "Amyloid beta protein in rat soleus muscle in chloroquine-induced myopathy using end-specific antibodies for A beta 40 and A beta 42: immunohistochemical evidence for amyloid beta protein", <i>Neurosci Letters</i> 202 (1-2): 77-80 (1995).	<input type="checkbox"/>
30	Turner et al, "Amyloids b40 and b42 are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with Maturation", <i>J Biol Chem</i> 271(15): 8966-8970.	<input type="checkbox"/>
31	Yanagisawa et al, "Fractionation of Amyloid b-Protein (Ab) in Alzheimer's Disease and Down's Syndrome Brains: Presence of Membrane-Bound Ab", <i>Ann NY Acad Sci</i> 786:184-194 (1996).	<input type="checkbox"/>
32	Jarrett, JT et al., "The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's Disease," <i>Biochemistry</i> 32:4693-4697 (1993b).	<input type="checkbox"/>
33	Saïdo et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <i>J. Biol. Chem.</i> 269(21):15253-15257 (1994).	<input type="checkbox"/>
34	Quitschke et al., "The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid β -protein precursor promoter," <i>J. Biol. Chem.</i> 271(36), pp. 22231-22239 (1996).	<input type="checkbox"/>
35	Saïdo et al., "Autolytic transition of μ -calpain upon activation as resolved by antibodies distinguishing between the pre- and post-autolysis forms," <i>J. Biochem.</i> 111:81-86 (1992).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402520
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

36	Saïdo et al., "In situ capture of mu-calpain activation in platelets," J. Biol. Chem. 268(10). (1993) (Abstract Only)	<input type="checkbox"/>
37	Busciglio, J et al., "Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells Proc Nat Acad Sci USA 90 2092-2096 (1993).	<input type="checkbox"/>
38	Haas, C. et al., "Amyloid beta-peptide is produced by cultured cells during normal metabolism," Nature 359 322-325 (1992).	<input type="checkbox"/>
39	Masters, CL et al., "Amyloid plaque core protein in Alzheimer disease and Down syndrome," Proc Nat Acad Sci USA 82 4245-4249 (1985).	<input type="checkbox"/>
40	Miller, DL et al., "Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's Disease," Arch Biochem Biophys 301:41-52 (1993).	<input type="checkbox"/>
41	Seubert, P et al., "Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids," Nature 359 325-327 (1992).	<input type="checkbox"/>
42	Gegeddes JW et al. (1999) "N-terminus truncated b-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease". Neurobiol of Aging 20, 75-79.	<input type="checkbox"/>
43	Haas C et al. (1993) "Cellular processing of B amyloid precursor protein and the genesis of amyloid B-peptide." Cell 75, <1039-1042	<input type="checkbox"/>
44	Higgins Is et al. (1996) "p3 amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain." Am. J. Pathol 149, 585-596.	<input type="checkbox"/>
45	Johnson-Wood K et al. "Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimer disease" Proc natl. Acad. Sci U.S.A. 1997 Feb. 18; 94 (4): 1550-5.	<input type="checkbox"/>
46	Laiowski M (1996) "Th nonamyloidogenic p3 fragment (amyloid b 17-42) is a major constituent of Down's syndrome cerebellar preamyloid." J biol Chem 271, 33623-31.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402620
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

47	Lamer AJ (1999) "Hypothesis: amyloid b peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease." Neurobiol. of Aging 20, 65-69	<input type="checkbox"/>
48	Nasuland et al (1994) "Relative abundance of Alzheimer Ab amyloid peptide variants in Alzheimer disease and normal aging." Proc. Natl. Acad. Sci. USA 91, 8378-8382.	<input type="checkbox"/>
49	Pike CJ et al (1995) "Amino-terminal deletions enhance aggregation of b-amyloid peptides in vitro." J Biol Chem 270, 23895-8.	<input type="checkbox"/>
50	Vigo-Pelfrey C et al (1993) "Characterization of beta-amyloid peptide from human cerebrospinal fluid." J Neurochem 61, 1965-8.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09402820
Filing Date	1999-10-12
First Named Inventor	Benjamin Chain
Art Unit	1645
Examiner Name	P. A. Duffy
Attorney Docket Number	20555/1203301-US1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/FB/ Flynn Barrison (53,970)	Date (YYYY-MM-DD)	
Name/Print	Mitchell Bernstein	Registration Number	46550

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.